Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022
02 August 2022 - 6:00AM
Business Wire
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”,
Nasdaq: ARCT), a global, late-stage clinical messenger RNA
medicines company focused on the development of infectious disease
vaccines and significant opportunities within liver and respiratory
rare diseases, today announced that it will release its financial
results for the quarter ended June 30, 2022 after the market close
on Tuesday, August 9 and will also host a conference call and
webcast at 4:30 pm Eastern Daylight Time on August 9, 2022.
Tuesday, August 9, 2022 @ 4:30 pm EDT Domestic:
1-800-263-0877 International: 1-323-794-2094 Conference ID: 8017918
Webcast: Link
About Arcturus Therapeutics
Founded in 2013 and based in San Diego, California, Arcturus
Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage
clinical mRNA medicines and vaccines company with enabling
technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA
Technology (samRNA) and (iii) mRNA drug substance along with drug
product manufacturing expertise. Arcturus’ diverse pipeline of RNA
therapeutic and vaccine candidates includes mRNA vaccine programs
for SARS-CoV-2 (COVID-19) and Influenza, and other programs to
potentially treat ornithine transcarbamylase (OTC) deficiency, and
cystic fibrosis, along with partnered programs including glycogen
storage disease type III, and hepatitis B virusArcturus’ versatile
RNA therapeutics platforms can be applied toward multiple types of
nucleic acid medicines including messenger RNA, small interfering
RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing
therapeutics. Arcturus’ technologies are covered by its extensive
patent portfolio (patents and patent applications issued in the
U.S., Europe, Japan, China and other countries). Arcturus’
commitment to the development of novel RNA therapeutics has led to
collaborations including, amongst others, Janssen Pharmaceuticals,
Inc., part of the Janssen Pharmaceutical Companies of Johnson &
Johnson, Ultragenyx Pharmaceutical, Inc., and the Cystic Fibrosis
Foundation. addition, please connect with us on Twitter and
LinkedIn. For more information visit www.ArcturusRx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220801005045/en/
IR and Media Contacts Arcturus Therapeutics
IR@arcturusrx.com
Kendall Investor Relations Carlo Tanzi, Ph.D. (617) 914-0008
ctanzi@kendallir.com
Arcturus Therapeutics (NASDAQ:ARCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arcturus Therapeutics (NASDAQ:ARCT)
Historical Stock Chart
From Apr 2023 to Apr 2024